Experts study implications of genetic markers in prostate cancer
“It really was a multidisciplinary effort to pull the data together [and] provide the clinical implications [of] the genetic markers,” says Veda N. Giri, MD.
In this video, Stacy Loeb, MD, MSc, and Veda N. Giri, MD, discuss the European Urology paper “Genetic Risk Prediction for Prostate Cancer: Implications for Early Detection and Prevention,” for which they served as coauthors. Giri is division chief of Clinical Cancer Genetics for Yale Cancer Center and Smilow Cancer and assistant director of Clinical Cancer Genetics for Yale Cancer Center, New Haven, Connecticut. Loeb is a professor in the departments of urology and population health at the NYU Grossman School of Medicine, New York City, New York.
Study links PARP inhibitors to increased risk of hematologic toxicity in mCRPC patients
November 23rd 2023A recently published study found an association between PARP inhibitor treatment and an increased risk of hematological adverse events, including anemia, thrombocytopenia, and neutropenia, in patients with metastatic castration-resistant prostate cancer.
Mistrust of medical research may discourage genetic testing in prostate cancer
November 20th 2023According to the survey, 79% of Black men know that genetic information can help improve prostate cancer outcomes, yet 33% indicated that they would be unwilling or uncertain to provide DNA samples, even if it meant finding new treatment options.
